{"id":54781,"date":"2023-03-13T20:04:21","date_gmt":"2023-03-13T19:04:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/"},"modified":"2023-03-13T20:04:21","modified_gmt":"2023-03-13T19:04:21","slug":"sensorion-discloses-no-exposure-to-silicon-valley-bank-closure","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/","title":{"rendered":"Sensorion Discloses No Exposure To Silicon Valley Bank Closure"},"content":{"rendered":"
\n

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

\nSensorion (FR0012596468 \u2013 ALSEN) <\/b>a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (\u201cFDIC\u201d) as receiver.\n<\/p>\n

\nSensorion does not expect any impact to its liquidity position or its ongoing operations as a result of the SVB closure.\n<\/p>\n

\nAbout Sensorion<\/b>\n<\/p>\n

\nSensorion is a pioneering clinical-stage biotech company, which specializes in the development of gene therapies to restore hearing loss disorders, a significant global unmet medical need.\n<\/p>\n

\nSensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.\n<\/p>\n

\nIt has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. OTOF-GT targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2<\/i> gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.\n<\/p>\n

\nSensorion\u2019s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders.\n<\/p>\n

\nSensorion\u2019s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.\n<\/p>\n

\nwww.sensorion.com<\/a>\n<\/p>\n

\nLabel: SENSORION
\n
<\/b>ISIN: FR0012596468
\n
<\/b>Mnemonic: ALSEN<\/b>\n<\/p>\n

\nDisclaimer<\/b>\n<\/p>\n

\nThis press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations<\/b>
David Lawrence, Chief Financial Officer (US\/UK)
\n
No\u00e9mie Djokovic, Investor Relations and Communications (Europe\/France)
\n
ir.contact@sensorion-pharma.com<\/a>\n<\/p>\n

\nInternational Media Relations<\/b>
Consilium Strategic Communications
\n
Matthew Cole\/Jessica Hodgson\/Sue Stuart
\n
+44 7593 572720
\n
+44 7561 424788
\n
Sensorion@consilium-comms.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (\u201cFDIC\u201d) as receiver. Sensorion does not expect any … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54781","6":"format-standard","7":"category-industry"},"yoast_head":"\nSensorion Discloses No Exposure To Silicon Valley Bank Closure - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (\u201cFDIC\u201d) as receiver. Sensorion does not expect any ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-13T19:04:21+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sensorion Discloses No Exposure To Silicon Valley Bank Closure\",\"datePublished\":\"2023-03-13T19:04:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/\"},\"wordCount\":560,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/\",\"name\":\"Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-13T19:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensorion Discloses No Exposure To Silicon Valley Bank Closure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/","og_locale":"en_US","og_type":"article","og_title":"Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Pharma Trend","og_description":"MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (\u201cFDIC\u201d) as receiver. Sensorion does not expect any ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-13T19:04:21+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sensorion Discloses No Exposure To Silicon Valley Bank Closure","datePublished":"2023-03-13T19:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/"},"wordCount":560,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/","url":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/","name":"Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-13T19:04:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sensorion-discloses-no-exposure-to-silicon-valley-bank-closure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sensorion Discloses No Exposure To Silicon Valley Bank Closure"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54781"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54781\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}